

Imugene Ltd

03:20 28 Jan 2020

Imugene will trial PD1-Vaxx in patients with non-small cell lung cancer

Imugene Limited (ASX:IMU) (OTCMKTS:IUGNF) will trial its PD1-Vaxx B-cell cancer immunotherapy on patients with non-small cell lung cancer (NSCLC) during 2020 at up to six sites in North America and Australia.

NSCLC is the most common type of lung cancer, accounting for around 80% of cases.

Important pre-clinical milestones have been met with GMP manufacturing, including final sterile fill and finish, processes completed by FDA inspected and qualified contract manufacturing organisations in the US.

"New therapeutic option"

The final filled and finished vials of PD1-Vaxx have completed non-human primate (NHP) safety toxicology studies at a US-based contract research organisation (CRO).

NHP was chosen due to its target PD1 receptor being 100% identical to human PD1 and, therefore, also provided valuable data on the antibody generating potential of PD1-Vaxx in humans.

Managing director and CEO Leslie Chong said, "We are pleased to reach both the toxicology and GMP drug product manufacturing milestones with such positive results, enabling us to progress PD1-Vaxx into Phase 1 trials in 2020 as an important next step in bringing a much-needed new therapeutic option to cancer patients".

Three doses tested

The three doses tested were not only well tolerated with no adverse findings reported, they also generated high levels of PD1-targeting polyclonal antibodies.

This is an important development since it's a strong indicator that PD1-Vaxx will break tolerance in humans, generate antibodies and may produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers.

These three doses will be selected for the dose-escalation phase of the Phase 1 trial set to begin in 2020.

Price: 0.057

Market Cap: \$251.29 m

1 Year Share Price Graph



Share Information

Code: IMU

Listing: ASX

52 week High Low
0.067 0.016

Sector: Pharma & Biotech

Website: www.imugene.com

Company Synopsis:

Imugene Ltd (ASX:IMU) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).